Vis, M., et al. (2008) IgM-Rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibri- nogen antibodies decrease during treatment with the tum- or necrosis factor blocker infliximab in patients with rh- eumatoid arthritis. Journal of Rheumatology, 35, 425-428.

has been cited by the following article:

• TITLE: Radon-therapy in ankylosing spondylitis reduces auto-antibody titers

  AUTHORS: Angelika Moder, Clemens Hufnagl, Martin Jakab, Wolfgang Hitzl, Markus Ritter

  KEYWORDS: Radon; CCP; Autoantibodies; Ankylosing Spondylitis

  JOURNAL NAME: Open Journal of Molecular and Integrative Physiology, Vol.1 No.3, November 4, 2011

  ABSTRACT: Combined low-dose radon/hyperthermia therapy has been reported to improve pain and mobility in patients with rheumatic disorders. The key feature of inflammatory rheumatic diseases is the induction of autoimmune processes via the production of autoantibodies. As reducing the autoantibody level through administration of biologicals is described to correlate with delay of disease progression, we investigated the impact of combined low-dose radon/hyperthermia therapy on the serum levels of antibodies directed against cyclic citrullinated peptides in patients with ankylosing spondylitis. We found that levels of circulating anti-CCP antibodies is significantly reduced immediately after a 3 weeks of radon therapy regimen.